Imugene snags Chinese patent for sublingual bone-loss drug; Florida researchers develop DNA 'nanotrain' for targeted delivery;

> Australian company Imugene won a Chinese patent for its delivery tech Linguet, a bone-loss drug for osteoporosis with a platform that allows absorption in the mouth. Release

> Researchers at the University of Florida developed a "DNA nanotrain" to carry cancer drugs and bioimaging agents to tumor cells in a cost-effective way. Story

> Emergent Technologies and Caisson Biotech, the team that created the HEPtune drug delivery system that enhances drugs by increasing their half-life, joined with Seton Healthcare Family to expand the system's use. Release

> Sensile Medical partnered with scPharmaceuticals to develop and manufacture an automated patch pump that delivers furosemide under the skin. Release

> Andain has developed an inhaled nanoparticle solution for the treatment of chronic obstructive pulmonary disease. The lipid-based nanoparticles absorb in the body with no adverse effects, the company says. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.